Rilotumumab

also known as AMG 102

Monoclonal antibody targets HGF, MET via inhibition

Developed for: gastric cancer · esophageal cancer · gastroesophageal junction adenocarcinoma · castration-resistant prostate carcinoma · fallopian tube carcinoma · gliosarcoma · malignant glioma · malignant pleural mesothelioma
+9 more
· metastatic prostate carcinoma · non-small cell lung carcinoma · ovarian carcinoma · primary peritoneal carcinoma · renal cell carcinoma · sarcomatoid mesothelioma · small cell lung carcinoma · squamous cell lung carcinoma · colorectal cancer
Investigated by: Amgen · National Cancer Institute (NCI) · Ahmad Tarhini · Gynecologic Oncology Group · Katy Peters · NantBioScience, Inc.
+3 more
· NantCell, Inc. · SWOG Cancer Research Network · UNICANCER

Trials 15

today NCT02137343 · Ph 3 NCT02926638 · Ph 2/3 NCT01791374 · Ph 1 NCT01697072 · Ph 3 NCT01233687 · Ph 1/2 NCT01443065 · Ph 2 NCT01039207 · Ph 2 NCT01113398 · Ph 2 NCT01105390 · Ph 2 NCT00719550 · Ph 1/2 NCT00791154 · Ph 1/2 NCT00770848 · Ph 1/2 NCT00788957 · Ph 1/2 NCT00422019 · Ph 2 NCT00427440 · Ph 2

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT01791374	Nov 2012 → Aug 2013	gastroesophageal junction adenocarcinoma	Amgen	Completed	No outcome recorded
Phase 1/25 trials
Phase 1/2	NCT01233687	Aug 2011 → Nov 2014	non-small cell lung carcinoma	Ahmad Tarhini	Completed	No outcome recorded
Phase 1/2	NCT00719550	Feb 2009 → Nov 2010	esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma	Amgen	Completed	No outcome recorded
Phase 1/2	NCT00791154	Dec 2008 → Feb 2010	small cell lung carcinoma	NantCell, Inc.	Terminated	No outcome recorded
Phase 1/2	NCT00770848	Nov 2008 → Jan 2011	castration-resistant prostate carcinoma, metastatic prostate carcinoma	Amgen	Completed	No outcome recorded
Phase 1/2	NCT00788957	Oct 2008 → Jul 2010	colon carcinoma, rectal cancer	NantBioScience, Inc.	Completed	No outcome recorded
Phase 26 trials
Phase 2	NCT01443065	Jan 2011 → Mar 2014	esophageal cancer, gastric cancer	UNICANCER	Completed	No outcome recorded
Phase 2	NCT01039207	Oct 2010 → Jul 2012	fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma	Gynecologic Oncology Group	Completed	No outcome recorded
Phase 2	NCT01113398	Aug 2010 → Nov 2014	gliosarcoma	Katy Peters	Completed	No outcome recorded
Phase 2	NCT01105390	Apr 2010 → May 2011	malignant pleural mesothelioma, sarcomatoid mesothelioma	National Cancer Institute (NCI)	Withdrawn	No outcome recorded
Phase 2	NCT00422019	Jan 2007 → Mar 2009	renal cell carcinoma	Amgen	Completed	No outcome recorded
Phase 2	NCT00427440	Nov 2006 → Dec 2008	malignant glioma	Amgen	Completed	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT02926638	Jun 2014 → Jan 2015	squamous cell lung carcinoma	SWOG Cancer Research Network	Terminated	No outcome recorded
Phase 32 trials · 1 missed
Phase 3	NCT02137343	Jul 2014 → Jun 2015	gastric cancer	Amgen	Terminated	No outcome recorded
Phase 3	NCT01697072	Oct 2012 → Nov 2014	gastric cancer	Amgen	Terminated	Missed primary

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2014-11-24	Amgen	Results Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer amgen.com ↗ Amgen (NASDAQ:AMGN) today announced the termination of all Amgen -sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 and RILOMET-2 studies.

All press releases naming this drug 1 release

Date	Issuer	Release
2014-11-24	Amgen	Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer amgen.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

Field	Value	Cited text
Known as	Rilotumumab	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02137343 ↗ 6 NCT00788957 ↗ NCT01697072 ↗ NCT01039207 ↗ NCT02926638 ↗ NCT01791374 ↗ NCT01105390 ↗
Known as	AMG 102	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00770848 ↗ 7 NCT00791154 ↗ NCT00719550 ↗ NCT01443065 ↗ NCT01233687 ↗ NCT00422019 ↗ NCT00427440 ↗ NCT01113398 ↗
Action	Inhibit	“Inhibition of both HGF/c-Met and EGFR pathways can be accomplished by utilizing the combination of AMG 102 and erlotinib in patients with advanced NSCLC.” NCT01233687 ↗
Modality	Monoclonal antibody	“Rilotumumab is a type of drug called a monoclonal antibody” NCT01039207 ↗ 1 CHEMBL1743063 ↗
Route	Intravenous	“IV (in the vein)” NCT00422019 ↗
Target	HGF	“Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF).” PMID 28958504 ↗ Sep 2017